Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 141-150 of 2785 for

Edit search filters
  1. Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

    Rochester, MN

  2. Bendamustine Hydrochloride and Rituximab with or without Bortezomib Followed by Rituximab with or without Lenalidomide in Treating Patients with High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

    Rochester, MN

  3. Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

    Rochester, MN

  4. Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma

    Rochester, MN

  5. A Trial of 15 Fraction vs 25 Fraction Pencil Beam Scanning Proton Radiotherapy After Mastectomy in Patients Requiring Regional Nodal Irradiation

    Scottsdale/Phoenix, AZ, Rochester, MN

  6. Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

    Rochester, MN, Jacksonville, FL

  7. Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)

    Rochester, MN

  8. SPORT-DMG

    Rochester, MN, Scottsdale/Phoenix, AZ

  9. Comparing Retreatment Of 177Lu-DOTATATE PRRT Versus Everolimus In Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial

    Scottsdale/Phoenix, AZ

  10. A Study of APG-2575 Alone or in Combination with Other Therapeutic Agents to Treat Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

    Jacksonville, FL

.

Mayo Clinic Footer